New cocktail of drugs targets Hard-to-Treat stomach cancer
NCT ID NCT06519591
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of four drugs—cadonilimab, LM-302, S-1, and paclitaxel—in 40 people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The drugs are given through a vein and directly into the abdomen to attack the cancer from multiple angles. The main goal is to see if this approach improves survival after one year and shrinks tumors enough to allow surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cadonilimab, LM-302, S-1, and paclitaxel
What this could lead to
If successful, this could offer a new treatment option for people with advanced gastric cancer that has spread to the lining of the abdomen, potentially improving survival and enabling surgery.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drug combination may cause significant side effects, and it is not yet known if it works better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Huangpu District, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••